Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Pyrilutamide (KX-826)
Also known as: KX-826, Pyrilutamide
Pyrilutamide (KX-826) is a topical androgen receptor antagonist developed by Kintor Pharmaceutical in China. It has completed Phase II trials in China for androgenetic alopecia with promising results and is currently in Phase III trials. It represents a next-generation topical anti-androgen with potentially higher potency than RU-58841 and a legitimate pharmaceutical development pathway.
Risk Level
Medium RiskDifficulty
Intermediate| CAS Number | 1946012-64-1 |
| Molecular Formula | C22H20ClF3N4O4S |
| Class | Other |
| Category | Hair Loss Compounds |
Mechanism of Action
Pyrilutamide binds to the androgen receptor with high affinity, preventing DHT from activating androgen-responsive genes in hair follicle dermal papilla cells. It acts as a competitive AR antagonist with reported binding affinity comparable to or exceeding enzalutamide. Like clascoterone, it is designed for topical use with minimal systemic absorption, aiming to avoid the sexual side effects associated with systemic anti-androgens and 5-AR inhibitors.
Dosing Research
Phase II trials used 0.5% solution applied topically once daily. Phase III trials are ongoing with similar concentrations. Not yet commercially available in any market. Chinese trials have shown statistically significant hair count improvements vs placebo at 24 weeks. Do not use research chemical versions of unknown purity.
Side Effects & Risks
Phase II data showed mild application site reactions. No significant systemic anti-androgenic effects reported in trials. Some Chinese trial participants reported mild scalp irritation. Full safety profile pending Phase III completion. Medium risk rating due to limited data and early stage of development. Avoid unregulated research chemical versions.
Research Studies
Related compounds
Finasteride
OtherFinasteride is a selective type II 5-alpha reductase inhibitor approved for male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). It reduces scalp DHT levels by approximately 60-70% and is one of only two FDA-approved oral medications for androgenetic alopecia. It has decades of clinical data supporting its efficacy.
Tamoxifen
OtherTamoxifen is a selective estrogen receptor modulator (SERM) that has been the gold standard for breast cancer treatment and prevention since the 1970s. It is one of the most widely used compounds in post-cycle therapy (PCT) for restoring endogenous testosterone production after anabolic steroid use.
Clomiphene Citrate
OtherClomiphene citrate is a SERM originally developed for female ovulation induction and widely adopted in PCT protocols and off-label male hypogonadism treatment. It is a racemic mixture of two geometric isomers, enclomiphene (trans) and zuclomiphene (cis), with differing estrogenic properties.
Anastrozole
OtherAnastrozole is a potent, selective non-steroidal aromatase inhibitor that reduces estradiol levels by approximately 80-85%. It is widely used in breast cancer treatment and is the most commonly employed AI during anabolic steroid cycles to manage estrogen-related side effects.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.